drugset / Trial / NCT07489703
SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II, open-label, single-arm study evaluating the efficacy and safety of SHR-A1811 (a HER2-targeted ADC) combined with AK112 (a PD-1/VEGF bispecific antibody) in patients with HER2-amplified or overexpressed locally advanced or metastatic NSCLC.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |